KALA KALA BIO, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1479419 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY72.9%
TTM EPS YoY196.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-345.3%
ROA-43.2%
ROIC (approx.)-1,688.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.5%
Debt / equity0.00x
Current ratio6.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.97x
Accruals ratio42.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $59,000 | $61,000 | $366,000 | $6.13M | $6.23M | $6.05M | $5.26M | $5.17M |
| SG&A expense | $1.66M | $1.74M | $9.86M | $4.53M | $4.64M | $4.59M | $4.20M | $4.40M |
| Operating income | -$1.72M | -$1.80M | -$10.22M | -$7.24M | -$11.03M | -$10.67M | -$9.46M | -$9.99M |
| Interest expense | — | — | $141,000 | $963,000 | $1.08M | $1.09M | $1.39M | $1.48M |
| Net income | -$1.58M | -$1.62M | $686,000 | -$7.56M | -$11.15M | -$8.95M | -$8.18M | -$8.95M |
| EBITDA | — | — | -$10.17M | -$7.11M | -$10.96M | -$10.60M | -$9.39M | -$9.93M |
| EPS (basic) | -21.32 | -0.14 | — | -1.07 | -85.64 | -70.49 | — | -1.93 |
| EPS (diluted) | -21.32 | -0.14 | — | -1.07 | -85.64 | -70.49 | — | -1.93 |
| Weighted avg. shares (diluted) | 74,159 | 11.87M | — | 7.04M | 130,262 | 126,917 | — | 4.63M |
| Balance sheet | ||||||||
| Cash & equivalents | $229,000 | $1.76M | $7.56M | $21.10M | $31.94M | $42.22M | $51.18M | $49.20M |
| Short-term investments | $7.00M | $7.00M | — | — | — | — | — | — |
| Current assets | $10.58M | $12.32M | $9.49M | $24.27M | $33.66M | $45.72M | $52.80M | $51.28M |
| PP&E, net | — | — | — | $603,000 | $657,000 | $695,000 | $749,000 | $762,000 |
| Total assets | $10.58M | $12.32M | $9.49M | $25.02M | $36.05M | $48.25M | $55.48M | $54.08M |
| Current liabilities | $1.54M | $1.56M | $2.49M | $32.57M | $16.02M | $22.98M | $16.96M | $23.87M |
| Short-term debt | — | — | — | $28.41M | $9.51M | $15.50M | $10.34M | $17.98M |
| Long-term debt | — | — | — | $26.95M | $18.79M | $15.12M | $20.10M | $17.16M |
| Total debt | — | — | — | $55.36M | $28.30M | $30.62M | $30.44M | $35.14M |
| Total liabilities | $1.54M | $1.56M | $2.49M | $33.69M | $39.26M | $42.54M | $43.15M | $47.22M |
| Shareholders' equity | $9.04M | $10.76M | $7.00M | -$8.66M | -$3.21M | $5.71M | $12.33M | $6.86M |
| Net debt | — | — | — | $34.26M | -$3.65M | -$11.60M | -$20.74M | -$14.06M |
| Shares outstanding | 19.34M | 18.59M | 556,995 | 7.43M | 6.68M | 6.45M | 6.09M | 4.61M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.53M | -$2.90M | -$4.56M | -$10.88M | -$16.56M | -$8.82M | -$4.60M | -$4.72M |
| Investing cash flow | $0 | -$7.00M | $0 | $1,000 | — | — | -$69,000 | -$90,000 |
| Financing cash flow | $0 | $4.10M | -$8.98M | $30,000 | -$2.53M | -$135,000 | $6.65M | -$180,000 |
| Depreciation & amortization | — | — | $54,000 | $128,000 | $67,000 | $68,000 | $69,000 | $63,000 |
| Stock-based compensation | -$136,000 | -$471,000 | $401,000 | $2.04M | $2.24M | $2.31M | $2.09M | $2.04M |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.